Scarica l'app Stockscreener
18.52
0.00%
0.00
Dopo l'orario di chiusura:
18.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
Aktis Oncology initiates phase 1b trial for lung cancer drug By Investing.com - Investing.com Canada
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. - Stock Titan
Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Form 144 AKTIS ONCOLOGY INC For: 26 September By Investing.com - Investing.com Nigeria
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. - Stock Titan
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan
Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6%Here's What Happened - MarketBeat
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22MFI Oversold - dars.gov.et
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Tidal Investments LLC Acquires New Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology at Morgan Stanley conference: platform bets and capital strength - Investing.com Canada
AKTS: Multi-tumor radiopharmaceuticals advance in phase I, backed by platform innovation and strong funding - TradingView
symbol__ Stock Quote Price and Forecast - CNN
AKTS Initiated Coverage by Oppenheimer -- Rating Set to Outperform - GuruFocus
Two New York investor events will include Aktis Oncology's CEO - stocktitan.net
Oppenheimer initiates Aktis Oncology stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer initiates Aktis Oncology stock rating at Outperform - Investing.com
Aktis Oncology (NASDAQ:AKTS) Trading Down 7.3%Should You Sell? - MarketBeat
Wellington Management Group LLP Takes $63.37 Million Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology $AKTS Shares Purchased by BlackRock Inc. - MarketBeat
AKTS Q2 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Net LossQuarterly Profit Report - vinanet.vn
Jupiter Topco LLC Invests $42.36 Million in Aktis Oncology $AKTS - MarketBeat
Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS - MarketBeat
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Margin Guidance - vinanet.vn
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - KING5.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Fade Trade - dars.gov.et
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Donchian Channel - careplusvn.com
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesDividend Cut Risk - dars.gov.et
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Profit Recovery Report - dars.gov.et
AKTS Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):